A Clinical Trial for Safety and Efficacy of Human Umbilical Cord Blood - Derived Mesenchymal Stem Cells To Enhance Tendon Graft Healing in Anterior Cruciate Ligament Reconstruction With 2 Years Follow-Up
ESSKA Academy. Moon S. May 12, 2018; 218162; FP49-838
Sang Won Moon
Sang Won Moon
Login now to access Regular content available to all registered users.

You can access free non-premium educational content on the ESSKA Academy Portal by registering for free as 'ESSKA Academy User' here
Discussion Forum (0)
Rate & Comment (0)
Objectives: Mesenchymal stem cells (MSCs) showed therapeutic potential to enhance tendon graft healing in anterior cruciate ligament (ACL) reconstruction of animal study. Allogenic hUCB-MSCs may be used safely without treatment related adverse event, and prevent tunnel enlargement and improve clinical results in human ACL reconstruction.

Methods: Thirty patients, who underwent ACL reconstruction, were enrolled consecutively. The patients were divided 3 groups by randomization. For group A, ACL reconstruction surgery without additional treatment was performed as a negative control group. For group B, hUSB_MSCs and hyaluronic acids mixture were applied on tendon-bone interface of femoral and tibial tunnels during ACL reconstruction surgery. For group C, only hyaluronic acids were applied as a positive control group. Finally, 27 patients were analyzed after exclusion of three patients (re-rupture 1, death 1, follow-up loss 1). Incidence of treatment-related adverse event (infection, tumor formation), clinical outcomes including second-look arthroscopic finding, and amount of tunnel enlargement were evaluated.

Results: There was no treatment-related adverse event in treatment groups. There was no significant difference between the groups in clinical outcomes such as KT-2000 (p=0.793), pivot shift test (p=0.9245), IKDC subjective score (p=0.8227), Tegner activity level (p=0.9927) and second-look arthroscopic findings (synovial coverage of the graft, p=0.613, condition of the graft, p=0.5606). Tunnel enlargement of stem cell treatment group (579.74 ± 389.85 mm3) is not different from negative (641.97 ± 455.84 mm3) and positive control (421.96 ± 274.83 mm3) groups (p=0.6468).

Conclusions: Allogenic hUCB-MSCs were used safely without treatment related adverse event for 2 years follow-up. But, it failed to show clinical advantage such as decrease of knee laxity or improvement of clinical outcomes, and prevention of tunnel enlargement postoperatively.

Anterior cruciate ligament (ACL); Human umbilical cord blood - derived mesenchymal stem cell (hUCB-MSC); Stem cell; tendon graft healing; healing; randomized control trial (RCT)
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings